India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical laboratories, institutions, guilds and medical federations have taken on the task of designing programs to end health illiteracy in order to have informed, educated, knowledgeable and empowered communities where their health and wellbeing are concerned. 19 September 2024
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Targeted alpha therapy (TAT), or radioligand therapy, is a recent hot area that attracted big pharmas like Bristol Myers Squibb and Novartis. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
Scientists from the Russian Institute of Immunology of the Federal Medical and Biological Agency (FMBA) say they have created the world's first allergy vaccine. 30 August 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
One of the largest pharmaceutical production facilities in the Russian North-West region will soon be built in the city of Pushkino by the local drugmaker Active Component enterprise, The Pharma Letter’s local correspondent reports. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
The Russian Ministry of Health has registered the third Russian generic of the original drug Ozempic (semaglutide) from Danish drugmaker Novo Nordisk. 8 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024
Major pharmaceutical multinationals are looking to collaborate with Indian drug firms, leveraging their cost-efficient manufacturing capabilities, robust supply chains, and innovative research potential. 31 July 2024
The Russian government will be ready to significantly increase state procurements of drugs against hepatitis C in case of reduction price for them both by global drugmakers and Russian pharmaceutical companies. 31 July 2024
As geopolitical tension intensifies between China and the US-led West, more Chinese biotechs are actively seeking growth opportunities in the vast emerging markets, or the markets outside the USA and European Union, especially the geographically nascent ASEAN region and the wealthy Middle East region. 18 December 2023
Russia has faced a shortage of Jaquinus/Xeljanz (tofacitinib), a drug to treat rheumatoid arthritis from US pharma giant Pfizer, reports The Pharma Letter’s correspondent. 13 December 2023
Protek, one of Russia's leading pharmaceutical distributors, will begin the supplies of an Ozempic (semaglutide) generic, originated by Danish diabetes care and obesity giant Novo Nordisk against diabetes mellitus to the Russian market by the end of this year, reports The Pharma Letter’s local correspondent. 12 December 2023
In a major crackdown, the US Food and Drug Administration (FDA) has been conducting an increased number of inspections of pharmaceutical manufacturing facilities in India. 7 December 2023
French drugmaker Sanofi is experiencing serious problems in Russia, as due to logistical problems, the company almost stopped exporting insulin from its Russian plant to the European Union. 6 December 2023
Russian drugmaker Basis-Metigreens together with the India’s Synmedic company plan to launch the production of an analogue of Ingavirin (pentandioici imidazolylaethanamidum), one of the most popular antiviral drugs in Russia, which is produced by the local Valenta Pharm, The Pharma Letter’s local correspondent reports. 5 December 2023
Several Latin American countries, given their processes of political change, are immersed in deep discussions about transforming their health systems, writes The Pharma Letter's local correspondent. 29 November 2023
Swiss pharma giant Roche will resume the supply of its cystic fibrosis drug Pulmozyme (dornase alfa), as the company has found the way for its imports to the Russian market, The Pharma Letter’s local correspondent reports. 29 November 2023
India's Draft Patents (Amendment) Rules, 2023, that propose several changes to India's patent regime, have raised significant concerns among public health experts, domestic drug industry chiefs, and civil society organizations. 28 November 2023
Russia will significantly reduce public procurements of anti-cancer drugs which are not included in the list of vital drugs due to the lack of funds, reports The Pharma Letter’s local correspondent. 28 November 2023
Artificial intelligence (AI) has become an integral part of our daily lives. Within the pharmaceutical industry, AI and machine learning (ML) are being harnessed to aid many aspects of drug development and data analysis. 27 November 2023
The ongoing conflict involving Israelis and Palestinians represents a long-term threat to the peace and stability of the Middle East, but it is also impacting the production and flow of medicines and other medical supplies in the region, writes The Pharma Letter’s local correspondent. 23 November 2023
Complex regional pain syndrome (CRPS) is a chronic and potentially debilitating neuropathic pain condition that typically affects an extremity, such as an arm or leg.1 22 November 2023
Russian pharmaceutical companies are eyeing expanding in the United Arab Emirates (UAE) by launching production of their drugs and establishing their manufacturing facilities in the local market. 22 November 2023
Indian pharmaceutical company Jodas Expoim is experiencing serious problems with the construction of its first enterprise in the Russian Federation. 21 November 2023
Even as India's drug pricing authority, the National Pharmaceutical Pricing Authority (NPPA) last week brought 33 fixed-dose combination (FDC) drugs under its price regulation, in an initiative to make these drugs more cost-effective, a recent comprehensive analysis reveals a concerning trend, that the Indian government's efforts to eliminate centrally unapproved and banned antibiotic FDC drugs have experienced limited success, reports The Pharma Letter’s India correspondent. 20 November 2023
The Russian Medical Research Company, which is a subsidiary of Swiss firm Genfa Global, is considering the production of Trilexa, which is a generic of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), a drug for treatment of cystic fibrosis from the USA’s Vertex Pharmaceuticals, The Pharma Letter’s local correspond reports. 15 November 2023
Insulin sales in Russia have hit a five-year low, as local patients and government agencies have stopped buying the product for future use, reports The Pharma Letter’s local correspondent. 14 November 2023